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Progression of non-alcoholic steatosis 
to steatohepatitis and fibrosis parallels 
cumulative accumulation of danger signals 
that promote inflammation and liver tumors in  
a high fat–cholesterol–sugar diet model in mice
Michal Ganz, Terence N Bukong, Timea Csak, Banishree Saha, Jin‑Kyu Park, Aditya Ambade,  
Karen Kodys and Gyongyi Szabo*
Abstract 
Background: Non‑alcoholic fatty liver disease (NAFLD) is becoming a pandemic. While multiple ‘hits’ have been 
reported to contribute to NAFLD progression to non‑alcoholic steatohepatitis (NASH), fibrosis and liver cancer, 
understanding the natural history of the specific molecular signals leading to hepatocyte damage, inflammation and 
fibrosis, is hampered by the lack of suitable animal models that reproduce disease progression in humans. The pur‑
pose of this study was first, to develop a mouse model that closely mimics progressive NAFLD covering the spectrum 
of immune, metabolic and histopathologic abnormalities present in human disease; and second, to characterize the 
temporal relationship between sterile/exogenous danger signals, inflammation, inflammasome activation and NAFLD 
progression.
Methods: Male C57Bl/6 mice were fed a high fat diet with high cholesterol and a high sugar supplement (HF–HC–
HSD) for 8, 27, and 49 weeks and the extent of steatosis, liver inflammation, fibrosis and tumor development were 
evaluated at each time point.
Results: The HF–HC–HSD resulted in liver steatosis at 8 weeks, progressing to steatohepatitis and early fibrosis at 
27 weeks, and steatohepatitis, fibrosis, and tumor development at 49 weeks compared to chow diet. Steatohepatitis 
was characterized by increased levels of MCP‑1, TNFα, IL‑1β and increased liver NASH histological score. We found 
increased serum levels of sterile danger signals, uric acid and HMGB1, as early as 8 weeks, while endotoxin and ATP 
levels increased only after 49 weeks. Increased levels of these sterile and microbial danger signals paralleled upregu‑
lation and activation of the multiprotein complex inflammasome. At 27, 49 weeks of HF–HC–HSD, activation of M1 
macrophages and loss of M2 macrophages as well as liver fibrosis were present. Finally, similar to human NASH, liver 
tumors occurred in 41% of mice in the absence of cirrhosis and livers expressed increased p53 and detectable AFP.
Conclusions: HF–HC–HSD over 49 weeks induces the full spectrum of liver pathophysiologic changes that charac‑
terizes the progression of NAFLD in humans. NAFLD progression to NASH, fibrosis and liver tumor follows progressive 
accumulation of sterile and microbial danger signals, inflammasome activation, altered M1/M2 cell ratios that likely 
contribute to NASH progression and hepatic tumor formation.
Keywords: Non‑alcoholic steatohepatitis (NASH), High fat diet with high cholesterol and a high sugar supplement 
(HF–HC–HSD), Inflammasome, Danger signals, Tumor
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Background
The prevalence of obesity is increasingly recognized as 
a pandemic that has been responsible for over 3.4 mil-
lion deaths in 2010 [1]. This condition affects both adults 
and children at an alarming rate with the well recog-
nized adverse health risk for the development of meta-
bolic diseases including non-alcoholic fatty liver disease 
(NAFLD). It has been reported that about 30% of the 
Western population suffers from NAFLD that increases 
to about 75% in obese individuals [2, 3]. NAFLD includes 
a wide spectrum of disease stages, ranging from steatosis 
alone, which is characterized by at least 5% triglyceride 
accumulation, to nonalcoholic steatohepatitis (NASH), 
which is characterized by liver fat accumulation and 
inflammation. Fibrosis is seen in 20% of NASH patients 
and hepatocellular carcinoma (HCC) develops in NASH 
livers even without cirrhosis [4–6]. Current treatment 
options for NAFLD are limited and ineffective [7, 8].
Non-alcoholic fatty liver disease in humans can be 
separated into NASH and non-NASH. Of the patients 
with steatosis alone, up to 20–30% can progress to NASH 
over 3 years [9], and it appears that the progression into 
NASH is more likely in the setting of associated risk fac-
tors, including insulin resistance, diabetes, and obesity 
[10, 11]. Various studies show that 20–50% of patients 
with NASH will display disease progression, either in 
the form of increased inflammation or liver fibrosis 
[12–14]. The presence of necrotic-inflammation her-
alds NASH progression into fibrosis [15]. Patients with 
NASH can develop HCC even in the absence of fibro-
sis and cirrhosis, with studies showing a 2–20% 5-year 
cumulative HCC incidence [16, 17]. Factors leading to 
progressive NASH and inflammation are not well under-
stood, although it has been agreed upon that multiple 
‘pathogenic hits’ are required for the progressive devel-
opment of liver disease.
Developing a mouse model that closely represents fea-
tures and progression of NAFLD in human disease has 
been a challenge. Of the different types of animal models 
of NAFLD/NASH, none demonstrates the entire spec-
trum of metabolic derangements and disease progression 
in humans. For example, there are studies from high fat 
diet (HFD) feedings that report features of steatohepati-
tis, fibrosis, and tumor development but lack the earlier 
steatosis phenotype [18, 19]. The genetically modified 
models show elements of NAFLD, but thus far have not 
shown the progression that mimics each stage of human 
NAFLD. The methionine and/or choline deficient diet 
models of NASH produce steatohepatitis with significant 
weight loss that is not characteristic of the human disease 
[20].
Increasingly, NAFLD progression to NASH with inflam-
mation has been proposed to involve inflammasome 
activation [21–23]. Inflammasome are multi-protein com-
plexes that play a key role in the modulation of innate 
immune responses. Inflammasomes function as sen-
sors of endogenous and exogenous damage-associated 
molecular patterns (DAMPs) and pathogen-associated 
molecular patterns (PAMPs), respectively which are pro-
duced during NAFLD progression to NASH. DAMPs are 
associated with ROS production, which are known to 
induce inflammasome activation resulting in the cleavage 
of effector pro-inflammatory cytokines such as pro-IL-1β 
and pro-IL-18 [24]. Given the key role played by inflam-
masome activation in mediating pathogenic hits during 
hepatic inflammation in NASH, mouse models of pro-
gressive NASH leading to tumor formation should char-
acterize this signaling pathway.
In this study we present findings that a high fat diet with 
high cholesterol and a high sugar supplement (HF–HC–
HSD) feeding to mice over 8-, 27- and 49-weeks results in 
progression of NAFLD to NASH, fibrosis and early liver 
tumor formation. We report that this diet formulation 
causes cumulative progressive ‘pathogenic hits’ in well 
characterized sterile and microbial danger signals result-
ing in steatosis, inflammation, fibrosis and ultimately 
tumorigenesis that closely mimic NAFLD progression in 
humans.
Methods
Animal studies
This study was approved by the Institutional Animal Care 
and Use Committee of the University of Massachusetts 
Medical School. Principles of laboratory animal care 
were followed. The experimental time line and setup of 
mouse feeding on chow diet and our novel high fat, high 
cholesterol, high sugar diet (HF–HC–HSD) is outlined in 
Additional file 1: Figure 1S. Male C57Bl/6 wild-type mice 
that were 8–10  weeks old (n  =  6–12 per group) (Jack-
son Laboratory, Bar Harbor, ME, USA) were fed either a 
control chow diet or a Western diet equivalent high-fat, 
high-carbohydrate diet [Surwit diet (58% kcal 35 g% fat)] 
supplemented with 10% cholesterol (Research Diets, New 
Brunswick, NJ, USA); with drinking water supplemented 
with a high-fructose corn syrup equivalent consisting of 
a total of 42 g/L of carbohydrates at a ratio of 55% fruc-
tose (Acros Organics, Morris Plains, NJ, USA) and 45% 
sucrose (Sigma-Aldrich, St. Louis, MO, USA) by weight, 
partially based on the study by Kohli et al. [19]. The mice 
were given ad libitum access to the food and water for 8, 
27 or 49 weeks. See Additional File 1: Figure 2S for diet 
details.
Biochemical analysis
Serum alanine aminotransferase (ALT) levels were meas-
ured using a kinetic method (D-TEK, Bethlehem, PA, 
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USA), and liver triglyceride levels were determined using 
an L-type triglyceride H kit (Wako Chemicals USA, Inc., 
Richmond, VA, USA), as we have previously described 
[25]. ATP in the serum was measured by a chemilumi-
nescence assay (CellTiter-Glo, Promega Corp., Madi-
son, WI, USA). Uric acid in the serum was measured by 
a fluorometric assay (Abcam, Cambridge, MA, USA). 
Serum endotoxin was measured using a cell based HEK-
blue LPS detection kit (Invivogen, San Diego, CA, USA). 
Blood glucose was measured using the CVS advanced 
glucose meter (AgaMatrrix Inc., Salem, NH, USA).
Caspase activity assay
Caspase-1 activity was determined using freshly prepared 
whole liver lysates with a colorimetric assay. The analysis 
was based on the cleavage of the WEHD-pNA (Trp-Glu-
His-Asp-p-nitroanilide) substrate (R&D Systems, Minne-
apolis, MN, USA).
Immunoprecipitation and Western blotting analysis
Equal amounts of proteins from liver lysates were pre-
cleared with protein A/G beads (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Beads were removed by 
centrifugation, and supernatants were incubated and 
rotated overnight at 4°C with 5 μg anti-HMGB1 (Abcam) 
or normal rabbit IgG (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) as IP negative control. The primary 
antibody used was 2  μg/mL anti-acetyl lysine antibody 
(Abcam, Cambridge, MA, USA). Detailed IP protocol was 
described in a previous manuscript [26]. For western blot 
analysis of p53, antibodies were obtained from Abcam.
Cytokine measurements
Mouse IL-1β enzyme-linked immunosorbent assay 
(ELISA) kit was purchased from R&D Systems (Min-
neapolis, MN, USA). Mouse MCP-1 ELISA kit was pur-
chased from Biolegend (San Diego, CA, USA).
Histopathological analysis
Sections of formalin-fixed livers were stained with hema-
toxylin-eosin and Sirius Red. Frozen samples were also 
stained with Oil-Red-O that was made at the optimal 
cutting temperature. Immunohistochemistry staining for 
cleaved PARP (Abcam, cat. # ab32064), alpha fetoprotein 
(AFP) (Abcam cat. # ab46799) or sonic hedgehog (shh) 
(Santa Cruz cat. # sc-9024) was performed in formalin-
fixed, paraffin-embedded liver sections according to the 
manufacturer’s specifications. Slides were analyzed using 
microscopy using ImageJ and Microsuite (Olympus Soft 
Imaging Solutions GmbH, Munster, Germany). This 
histopathology was independently analyzed by a veteri-
nary pathologist (JKP) in a blinded manner (see “Author 
contributions”).
Glucose tolerance tests (GTT)
Insulin levels were measured 1 week prior to sacrificing 
the mice following an overnight fast. Mice were injected 
i.p. with 40% glucose (Sigma, St. Louis, MO, USA) at 
2 mg/kg body weight. Blood was collected by facial vein 
puncture prior to glucose injection and 30 min after glu-
cose injection. Blood was used for serum insulin meas-
urement using a mouse enzyme-linked immunosorbent 
assay kit (ALPCO, Salem, NH, USA).
RNA analysis
RNA was purified using a RNeasy kit (Qiagen Sciences, 
Germantown, MD, USA) with the on-column DNA 
digestion (Qiagen Sciences, Germantown, MD, USA). 
Complementary DNA was transcribed using a reverse-
transcription system (Promega Corp., Madison, WI, 
USA). Real-time quantitative polymerase chain reaction 
(qPCR) was performed with an iCycler (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA) using SYBR Green 
as the detector of double-stranded DNA, as previously 
described [27].
Flow cytometry
Isolated liver mononuclear cells (LMNCs) were re-
suspended at a concentration of approximately 1 ×  106 
cells per 50 μL in FACS staining buffer containing anti-
mouse CD16/CD32 mAb (2.4G2) from BD Pharmingen 
(San Jose, CA, USA) to block nonspecific binding to Fcγ 
receptors and incubated for 10  min at 4°C. Cells were 
stained with live/dead Fixable Blue Dead Cell Stain Kit 
from Life Technologies (Grand Island, NY, USA) to gate 
out dead cells. Further, we added the antibodies: CD11b 
APC, NK1.1 PE, CD3 Pacific Blue, Ly6C FITC (eBiosci-
ence, San Diego, CA, USA) to the cells and incubated for 
30  min in the dark at 4°C. For the negative control, the 
cells were stained with isotype-matched control antibod-
ies (eBioscience, San Diego, CA, USA). The cells were 
washed with FACS staining buffer by centrifugation at 
1,500 rpm for 5 min at 4°C and fixed with 1% paraform-
aldehyde. The cells were acquired on a BD LSR II instru-
ment (BD Biosciences, San Jose, CA, USA) and the data 
was analyzed by FlowJo software.
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assay was performed 
on nuclear proteins extracted from mouse liver sam-
ples. Briefly, double-stranded NF-κB oligonucleotide, 
5′AGTTGAGGGGACTTTCGC3′ was end labeled with 
γ32P-ATP (PerkinElmer, Waltham, MA, USA) using T4 
polynucleotide kinase. Total nuclear protein extract 
(4  µg) was incubated with 1  µL labeled oligonucleotide 
(50,000  cpm) and 4  µL dI-dC (Affymetrix Inc., Santa 
Clara, CA, USA) and 5× gel buffer [containing 20 mM 
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HEPES pH 7.9 (Sigma, St. Louis, MO, USA), 50  mM 
KCl (Sigma, St. Louis, MO, USA), 0.1 mM EDTA (Bos-
ton BioProducts Inc., Ashland, MA, USA), 1 mM DTT 
(Sigma, St. Louis, MO, USA), 5% glycerol (Fisher Sci-
entific, Fair Lawn, NJ, USA), 200  µg/mL BSA in sterile 
water] to a final 20 µL final volume made up with nucle-
ase-free water. Cold competition reaction used 20-fold 
excess NF-κB specific unlabeled double-stranded oligo-
nucleotide to the reaction mixture 20 min prior to add-
ing the 32P-labeled oligonucleotide. Reaction samples 
were incubated at room temperature for 20  min and 
resolved on a 4% polyacrylamide gel. Gels were dried 
and exposed to an X-ray film at −80°C for 6  h. Kodak 
X-OMAT 2000A Processor was used for X-ray film 
development.
Statistical analysis
Statistical significance was determined using the non-
parametric Kruskal–Wallis test and the Mann–Whitney 
test when appropriate. Data are presented as means and 
standard errors and are considered statistically signifi-
cant for p ≤ 0.05.
Results
HF–HC–HSD results in increased liver/body weight ratio 
and elevated insulin levels
Mice on a HF–HC–HSD showed sustained weight gain 
throughout the 49-week feeding period compared to 
chow diet-fed controls (Figure  1a). We chose to study 
male mice based on our previous observation that only 
male and not female mice develop steatohepatitis and 
insulin resistance after 16 weeks of HFD [21]. In the male 
mice, weight differences were statistically different at all 
time points starting at week 4 (Figure 1a). There was no 
significant difference in the liver/body weight ratio at the 
8-week time point, but the liver–body weight ratio was 
significantly increased at both 27 and 49  weeks in the 
HF–HC–HFD group compared to mice on the chow diet 
(Figure 1b).
To test insulin resistance, a characteristic of human 
NAFLD/NASH, serum insulin levels were evaluated 
before and 30 min after glucose injection. Baseline serum 
glucose was higher in HF–HC–HSD fed mice at all time 
points and significant at weeks 8 and 49 compared to 
match controls (Figure 1c). Baseline serum insulin levels 
prior to glucose injection showed a significant increase at 
27 and 49 weeks in mice fed a HF–HC–HFD compared 
to controls (Figure 1d). Serum insulin at 30 min after glu-
cose injection showed an increase at 7, 26, and 48 weeks 
in mice with HF–HC–HFD compared to chow controls, 
however the increase was statistically significant only at 
8  weeks most likely owed to high individual variability 
(Figure 1d).
Steatosis is present throughout the HF–HC–HSD feeding
Obesity and high insulin levels are often associated with 
fatty liver in humans [10, 11]. In mice that received the 
HF–HC–HSD, we found liver steatosis as assessed by 
Oil-Red-O staining (Figure  1e). Liver triglyceride lev-
els were significantly and equally increased in the HFD 
compared to the chow diet group at all time points 
(Figure  1f ). Liver damage, assessed by serum ALT, was 
increased at all time points on HF–HC–HSD compared 
to chow diet (Figure 1g).
Liver inflammation and inflammatory cytokines gradually 
increase over time in the HF–HC–HSD feeding
Hematoxylin and Eosin (H&E) staining revealed the 
presence of inflammatory cells in HF–HC–HFD liver 
(Figure  2a) and histology scoring by a histo-pathologist 
confirmed the presence of inflammation at 8, 27 and 
49 weeks (Figure 2b). The extent of inflammation gradu-
ally increased from lobular (8 weeks) to portal (27 weeks) 
inflammation. Hepatocyte ballooning [sonic hedgehog 
(shh) positive] [28] (Additional file 1: Figure 3S) increased 
at 27  weeks and fibrosis was detectable at 27  weeks. 
Necrosis, lobular, portal inflammation and fibrosis 
became prevalent at 49 weeks (Figure 2b). This data sug-
gests that robust inflammation in the liver in this mouse 
model occurs at the later stage of NASH by 49 weeks of 
HFD feeding.
Next, we evaluated specific markers of inflammation. 
The chemokine monocyte chemoattractant protein 1 
(MCP-1) contributes to steatosis and inflammatory cell 
infiltration, and is increased during fibrogenesis [29, 
30]. There was a significant increase in MCP-1 at both 
the mRNA (Figure  2c) and protein (Figure  2d) levels at 
27 and 49 weeks. Furthermore, the increase in MCP-1 at 
49 weeks was significantly higher compared to 27 weeks 
of feeding with HF–HC–HSD. Tumor necrosis factor α 
(TNFα) mRNA was significantly increased in the liver 
at 27 and 49  weeks HF–HC–HSD feeding compared to 
chow fed controls (Figure  2e). Interleukin-1β (IL-1β) 
mRNA expression was increased in the liver at 27 and 
49 weeks (Figure 2f ) and IL-1β protein levels were signifi-
cantly increased in the serum at 49 weeks (Figure 2g). It 
is important to note that IL-1β was undetectable in the 
serum at the earlier time points (8 and 27  weeks) sug-
gesting that IL-1ß and most inflammatory markers show 
a significant increase at the later stage of non-alcoholic 
steatohepatitis. Pro-inflammatory cytokine gene expres-
sion is regulated by the nuclear factor kB [26]. We found 
no significant increase in NF-kB activation and DNA 
binding in livers after 8 weeks of HF–HC–HSD; however, 
there was a progressive and significant increase in NF-kB 
nuclear binding at 27 and 49 weeks compared to controls 
(Figure 2h).
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Figure 1 HF–HC–HSD leads to an increase in liver to body weight ratio, insulin resistance and steatohepatitis. Male C57Bl/6 mice were fed with 
either a high fat diet supplemented with 10% cholesterol and sucrose and fructose in the drinking water, or with a control chow diet for 8, 27, or 
49 weeks. Body weight over time (a) and liver to body weight ratio (b) is shown at each time point. Blood glucose (c) over time is shown for each 
time point. Insulin levels are shown in the chow fed and HFD fed mice both before and 30 min post glucose injection (d). Liver tissue was subjected 
to (e) Oil‑Red‑O staining. One representative slide from n = 6/group is shown. Liver triglyceride levels (f) and serum alanine aminotransferase 
(ALT) levels (g) were measured at each time point. *p < 0.01. n = 6–12/group. #p < 0.01—compared to HFD prior to glucose injection, +p < 0.01, 
++p = 0.02—compared to mice fed chow diet prior to glucose injection. n = 6–12/group.
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Inflammasome components are upregulated after 27 
and 49 weeks of HF–HC–HSD feeding
To explore inflammatory pathways that might be acti-
vated in the HF–HC–HSD NASH model, we evaluated 
the components, ligands and activation of the inflam-
masome. The inflammasome is a multi-protein complex 
that includes the NLR sensors and the adapter, ASC, 
which leads to assembly and activation of pro-caspase-1 
leading to its cleavage and activation of caspase-1, which 
leads to mature IL-1ß production [31, 32]. We found an 
increase in the mRNA levels of inflammasome sensors, 
NLRP3 (Figure 3a) and Pannexin-1 (Figure 3b) after both 
27 and 49  weeks HF–HC–HSD feeding. P2X7 mRNA 
was increased at all time points (Figure  3c), whereas 
ASC (Figure  3d) and caspase-1 (Figure  3e) were signifi-
cantly increased after 49 weeks HF–HC–HSD. We found 
increased caspase-1 activity at all time points of the HF–
HC–HSD (Figure  3f ) which was associated by detect-
able and high levels cleaved PARP indicating apoptosis at 
week 49 of HF–HC–HSD feeding (Figure 3g).
Danger signals accumulate during the progression 
of NAFLD/NASH in the HF–HC–HSD model
Inflammation and inflammasome activation are 
responses of the liver immune cells to endogenous and 
pathogen-derived danger signals [33]. Activation of the 
inflammasome typically occurs in response to two sig-
nals, triggering a TLR and NLR-mediated activation [24, 
31–33]. To identify potential triggers of inflammation in 
the HF–HC–HSD model of NAFLD/NASH, we evalu-
ated the presence of sterile and microbial danger signals 
that are known to activate the inflammasome. We found 
a modest, 1.5-fold, increase in serum uric acid levels, an 
activator of the NLRP3 inflammasome, at all time points 
in HF–HC–HSD mice compared to controls (Figure 3h). 
The levels of ATP, a danger signal released by damaged 
cells that stimulates the inflammasome via the P2X7 
receptor, showed a significant increase only at 49 weeks 
(Figure 3i). High-mobility group box1 (HMGB1) protein 
is a nuclear protein that is released by stressed and dam-
aged cells into the cytosol [34]. We found an increase in 
total HMGB1 levels in the liver after feeding with HF–
HC–HSD with a maximal increase at 27  weeks (Fig-
ure  3j). The activated form of HMGB1, acetyl-HMGB1, 
was also increased at both 8 and 27 weeks HF–HC–HSD 
(Figure 3k). We also found an increase in the mRNA lev-
els of the receptors that can sense HMGB1, including 
TLR2 (Figure  3l), TLR 4 (Figure  3m), TLR9 (Figure  3n) 
and RAGE (Figure 3o).
Finally, we evaluated the serum levels of the gut-derived 
exogenous danger signal, endotoxin, (lipopolysaccharide, 
LPS). LPS is a component of Gram negative bacteria, a 
major activator of Kupffer cells in NASH, which typically 
is the first signal in inflammasome activation [35]. Impor-
tantly, LPS was significantly increased after 49 weeks of 
HF–HC–HFD although it showed a trend of increase 
even at the earlier time points (Figure 3p). Liver expres-
sion of the LPS receptor, TLR4, at the mRNA level was 
also increased in the HF–HC–HSD fed mice at 27 and 
49 weeks compared to controls (Figure 3m). These results 
demonstrated that after 49  weeks of HF–HC–HSD a 
combination of sterile danger signals are present together 
with increased circulating levels of LPS that all contrib-
ute to inflammasome activation and upregulation of the 
inflammatory cascade.
Long‑term HF–HC–HSD is associated with Kupffer 
cell/macrophage activation and changes in M1/M2 
macrophage phenotype in the liver
Recruitment of inflammatory macrophages and Kupffer 
cell (KC) activation are key elements in the pathogen-
esis of NASH [36]. We found a progressive increase in 
the expression of macrophage/KC inflammatory mark-
ers F4/80 (Figure  4a), CD11b (Figure  4b) and CD68 
(Figure  4c) in the liver with HF–HC–HSD, starting at 
27  weeks. In contrast to the progressively increasing 
expression KC/macrophage markers, M2 macrophage 
markers, CD163 (Figure  4d) and Arg1 (Figure  4e), were 
both significantly decreased in the 49-week HF–HC–
HSD fibrotic livers suggesting the predominance of M1 
macrophages.
CD3 mRNA (Figure  4f ) expression increased at 
27  weeks on HF–HC–HSD feeding. Flow cytometry 
analysis of liver mononuclear cell populations after 
49 weeks of HF–HC–HSD, revealed an increased CD3+ 
T cell (Figure 4g, h) and inflammatory monocyte popula-
tion, identified by CD3−/NK1.1− then CD11b+/Ly6C+ 
[37] (Figure 4g, i), which is consistent with the increase 
in inflammatory cells in the long-term high-fat/sugar 
diet feedings [38–40]. There was however no significant 
(see figure on previous page.)
Figure 2 Long‑term HF–HC–HSD results in hepatic inflammation. Representative H&E (a) slides of chow and HFD fed mice are shown at each time 
point. Histology scoring was performed on tissue sections at 8, 27 and 49 weeks (b). MCP‑1 levels in the liver were evaluated at both the c mRNA 
and d protein level. Liver TNFα mRNA was evaluated (e). We also looked at IL‑1β mRNA in the liver (f) and IL‑1β protein levels in the serum (g). IL‑1β 
was undetectable in the serum at 8 and 27 weeks. Electrophoretic mobility assay was performed from nuclear extracts for NFκB at 8,27 and 49 weeks 
compared to control chow diet (h). *p < 0.01, **p = 0.02, %p = 0.05 versus chow fed controls, n = 6–12/group.
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change in NK cell population after 49 weeks of HF–HC–
HSD (Figure 4g, j). We observed a reduction in NKT cell 
population in the liver after 49  weeks of HF–HC–HSD 
compared to match controls (Figure  4g, k) consistent 
with the accumulation of inflammatory monocytes as 
similarly reported [38–40].
Differentiation of monocytes and polarization of mac-
rophages into classical (M1) inflammatory or alternative 
(M2) macrophages is determined by the tissue environ-
ment and contribute to the outcome of inflammation [41]. 
Consistent with the increase in MCP-1, a macrophage 
chemoattractant, at 27  weeks (Figure  2c, d), increase in 
inflammatory macrophages did not begin until 27 weeks 
(Figure  4a–c). At 49  weeks, these MØ activation mark-
ers were significantly increased compared to either the 
chow diet mice or the 8 and 27-week HF–HC–HSD fed 
(See figure on previous page.)
Figure 3 Long‑term HF–HC–HSD induces inflammasome upregulation and activation as well as upregulation of danger signals. Hepatic mRNA 
expression of the inflammasome components NLRP3 (a), Pannexin‑1 (b), P2X7 (c), ASC (d), and caspase‑1 (e), were measured using qPCR at each of 
the different HF–HC–HSD time points. Activation of inflammatory caspases was evaluated by measurement of caspase‑1 activity (f). Cell death was 
assessed by immunohistochemistry of cleaved PARP (g) on paraffin embedded liver sections. Level of danger signals in the serum, uric acid (h), ATP 
(i) were determined. Western blot was performed to determine levels of total HMGB1 (j) and immunoprecipitation and western blot for the active 
form of HMGB1, acetyl‑HMGB1 (k). Hepatic mRNA expression of receptors for danger signals, TLR2 (l), TLR4 (m), TLR9 (n) and RAGE (o) were measured 
using qPCR. Serum endotoxin was measured at 8, 27 and 49 weeks of HF–HC–HSD (p). *p < 0.01, **p = 0.02, ^p = 0.03, #p = 0.04 versus chow fed 
controls, n = 6–12/group.
Figure 4 M1 macrophage markers are increased, whereas M2 macrophage markers are decreased with long‑term HFD feeding. F4/80 (a), CD11b 
(b), and CD68 (c) mRNA levels were evaluated using qPCR to look for the presence of M1 macrophages. qPCR was also used to look for the presence 
of M2 markers CD163 (d) and Arg1 (e) mRNA levels. mRNA expression of CD3 in liver samples was determined by qPCR (f). FACS was performed 
to determine levels of CD3 (g, h), inflammatory monocytes (g, i), NK cells (g, j) NKT cells (g, k). *p < 0.01, **p = 0.02, versus chow fed controls, 
n = 6–12/group.
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mice. This pattern of macrophage expression was similar 
to the expression profile of inflammation and inflamma-
some activation (Figures 2, 4). The increase in TNFα and 
MCP-1, as shown earlier, in addition to the increase in 
KC/macrophage markers, is consistent with an increase 
in the M1 macrophage population [41].
Long‑term HF–HC–HSD results in liver fibrosis and tumor 
development
Inflammation in human NASH is associated with pro-
gressive disease and liver fibrosis and predisposes to 
hepatocellular cancer [42, 43]. We found expression of 
early markers of fibrogenesis in the liver at 27 weeks and 
this progressed further after 49-weeks of HF–HC–HSD 
feeding. Messenger RNA levels of α-smooth muscle actin 
(αSMA) were significantly increased at 27  weeks (Fig-
ure 5a) and pro-collagen1 mRNA was increased at both 
at 27 and 49  weeks of HF–HC–HSD feeding compared 
to age matched chow-fed controls (Figure  5b). We also 
observed an increase in transforming growth factor beta 
(TGFβ) at both 27- and 49-weeks HF–HC–HSD, con-
sistent with the development of fibrosis at these time 
points (Figure 5c). Additionally, increased mRNA expres-
sion of TIMP-1 (Figure 5d) and TIMP-3 (Figure 5e) was 
observed from 27- or 49-weeks respectively with signifi-
cant increase of MMP-2 (Figure 5f ) from 27-weeks com-
pared to controls. MMP-9 (Figure  5g) expression levels 
increased but not significantly at 49-weeks. Sirius red 
staining indicated fibrosis in livers of HD-HC-HSD mice 
(Figure 5h). Using histological scoring, there was signifi-
cantly more fibrosis at 49 weeks than at 27 weeks in the 
HC–HC–HSD-fed mice (Figure  2b). Additionally, HF–
HC–HSD feeding resulted in CD133 (Figure 6a) increase 
at 49-weeks, no significant change in Nanog (Figure 6b) 
and a significant increase in vimentin (Figure  6c) from 
27-weeks. Finally, after 49 weeks of feeding of HF–HC–
HSD we found tumors (or multiple tumors) in 41% (5/12) 
of the mice; these tumors were classified as hepatic ade-
nomas based on histopathology (Figure 6d). Higher p53 
protein levels at weeks 27 and 49 (Figure 6e) and low but 
detectable AFP (Figure 6f ) in some tumor areas though 
most tumors were negative for AFP. The representative 
liver tumor H&E histology presented in Figure 6d (HF–
HC–HSD 49-weeks) shows cells that closely resemble 
Figure 5 Long‑term HF–HC–HSD induces hepatic fibrosis. Hepatic mRNA expression of αSMA (a), pro‑collagen‑1 (b), TGFβ (c), TIMP‑1 (d), TIMP‑3 
(e), MMP2 (f), and MMP‑9 (g) were measured using qPCR in male mice at each time point. Representative images of Sirius red staining to evaluate 
fibrosis at 27 and 49 weeks are shown (h).
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normal hepatocytes on the upper left, but the neoplas-
tic liver tissue on the central-to-right and lower portion 
of the presented histology is composed of disorganized 
hepatocyte cords and does not contain a normal lobular 
architecture with marked steatosis, but no inflammation, 
and lacks cytologic atypia consistent with the histopatho-
logical observation of a liver adenoma [44, 45]. Addition-
ally, immuno-histology of tumors observed at week 49 
shows low but detectable AFP expression suggesting liver 
progenitor features [46, 47], but most tumor sections at 
49 weeks of HF–HC–HSD were AFP negative consistent 
with liver adenomas [44, 45]. There were no tumors in 
the chow-fed control group at any time point or after 8 
and 27 weeks of HF–HC–HSD.
Discussion
Non-alcoholic fatty liver disease is an emerging world-
wide epidemic yet the understanding of the mechanism 
and factors that lead to disease progression is limited. 
Our study describes a NAFLD model in mice that closely 
mimics the stages of human NAFLD. We show that a 
close mimic of the Western diet by feeding mice a HFD 
supplemented with cholesterol and high fructose corn 
syrup results in progressive development of NAFLD/
NASH and fibrosis. While other diet models of NASH 
use similar fat and glucose diet content, our novel diet 
has a 10% cholesterol content compared to 0–2% content 
in previous described diet [48–50]. We found evidence 
of steatosis without significant inflammation at 8 weeks, 
consistent with the non-NASH phenotype, in human 
NAFLD. By 27 weeks, there was evidence of steatohepa-
titis and early signs of fibrosis and by 49  weeks, NASH 
progressed to fibrosis and it was associated with liver 
tumor development. These stages are consistent with the 
progression of NAFLD in humans [2].
There was a gradual and progressive increase in the 
inflammatory markers TNF-α and MCP-1 throughout 
feeding with the HF–HC–HSD, suggesting that inflam-
mation increases as the length of the feeding increases. 
Both of TNFα and MCP-1 could drive inflammation in 
NASH. MCP-1 has multiple roles in steatohepatitis. It 
is a mediator of steatosis and plays a pivotal role in the 
recruitment of inflammatory cells [29]. MCP-1 adminis-
tration to primary murine hepatocytes results in triglyc-
eride accumulation [51]. Recruitment of macrophages 
to the liver was attenuated in MCP-1 knockout mice in 
alcohol-induced steatohepatitis [52]. Thus, MCP-1 could 
be one of the driving forces behind steatosis, inflamma-
tion, and an increase in liver macrophage population, 
which we found following a HF–HC–HSD.
IL-1β is an important pro-inflammatory cytokine that 
amplifies inflammation and sensitizes hepatocytes to 
TNF induced liver damage [25]. IL-1β secretion is largely 
the result of the activation of the inflammasome com-
plex [24]. Based on the observation that inflammasome 
activation began as early as 8 weeks, with an increase in 
caspase-1 activity, we hypothesize that the inflamma-
some activation is present with disease progression. The 
inflammasome has been previously described to play 
a role in other NASH models [22, 30, 31]. We found a 
Figure 6 Long‑term HF–HC–HSD induces hepatic tumor development. Liver mRNA was determined for CD133 (a), Nanog (b) and vimentin (c) 
by qPCR. Gross images of tumors that were detected in two of the mice and tumor histopathology (d). Detectable liver p53 protein expression 
was observed by western blotting after 27 and 49 weeks of HF–HC–HSD (e). Low but detectable AFP was observed in liver tumor samples after 
49 weeks of HF–HC–HSD on immunohistochemistry (f). *p < 0.01, #p = 0.03, %p = 0.05 versus chow fed controls, n = 6–12/group.
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minimal increase in expression of inflammasome compo-
nents starting at 8 weeks and a more prominent increase 
was seen at 49 weeks. Furthermore, IL-1β mRNA in the 
liver and IL-1β protein in the serum were significantly 
elevated at 49 weeks which was associated with a signifi-
cant increase in NF-kB nuclear binding. Inflammasome 
activation requires two signals for IL-1β production [24]. 
The first signal results in up-regulation of mRNA levels of 
the inflammasome components, and the second leads to 
protein production, particularly IL-1β. Our observations 
suggest that likely danger signals, such as uric acid, ATP, 
increased NF-kB nuclear binding and LPS are increased 
in a cumulative way in the HF–HC–HSD feeding and 
lead to IL-1β production at 49 weeks. Given the signifi-
cant increase in serum IL-1ß levels at 49 weeks and the 
equally moderate elevation in caspase-1 activity at 8, 
27 and 49  weeks, we cannot rule out that mechanisms 
other than inflammasome-mediated caspase-1 contrib-
ute to the IL-1ß increase in the advanced stage of NASH 
in our model. Previous studies found pro-IL-1ß cleavage 
by cathepsin B [53] which may be relevant in our model. 
This contention is also supported by observations where 
deficiency of inflammasome components failed to pre-
vent NASH in experimental models [22].
It has been proposed that development of NASH 
occurs either via multiple hits or parallel hits. The “two-
hit model” proposes that after a first hit, in this case stea-
tosis, another hit is needed (potentially LPS) to develop 
NASH [54]. The multiple parallel hit model was proposed 
by Tilg and Moschen, who propose that there are multi-
ple hits that act in parallel that lead to NASH, particularly 
adipose-tissue and gut-derived factors, as well as endo-
plasmic reticulum (ER) stress [55]. Our model appears 
to be consistent with the multiple parallel hit models, 
as it takes consecutive danger signals over time, such as 
uric acid and HMGB1 initially with subsequent increases 
in endotoxin and ATP later. The release of endogenous 
danger signals is highly plausible as necrosis on histol-
ogy appeared before significant increase in inflammation. 
We hypothesize that multiple sterile danger signals and 
cumulative stimulating effects in inflammatory cells are 
needed for NASH progression.
Damage-associated molecular patterns are known 
to play a role in liver injury and inflammation [34]. We 
evaluated the levels of various DAMPs in our HF–HC–
HSD feeding and their associated receptors and found 
an increase in a number of DAMPs. We found that total 
high mobility group box1 (HMGB1) protein and its active 
form, acetyl-HMGB1 were elevated, however did not 
appear to be sufficient to result in inflammation and fibro-
sis at 8 weeks. We also detected increases in the mRNA 
levels of the HMGB1 sensing receptors TLR2, TLR4, and 
TLR9 at 27 and 49-weeks, and an increase in RAGE at 
8  weeks. HMGB proteins bind to nucleic acids and are 
thought to act in complex with other proinflammatory 
mediators, such as endotoxin and IL-1β, to trigger inflam-
mation [34]. HMGB1 protein levels were also shown to be 
increased in the livers of mouse fed a methionine–choline 
deficient diet [23]. In addition to HMGB1, the levels of 
uric acid, a trigger of Nlrp3 inflammasome activation, are 
also elevated in the HF–HC–HSD model. Furthermore, 
an elevation of endotoxin and ATP was only seen after 
49  weeks of HF–HC–HSD, and their associated recep-
tors TLR4 and P2X7, respectively, were also increased at 
this time point. In our model, we see the most significant 
inflammation after 49  weeks of HF–HC–HSD, where 
there is an increase in both endotoxin and IL-1β, which 
may the necessary mediators for NASH progression.
These observations support that the gradual progres-
sion of NASH/fibrosis in the HF–HC–HSD feeding is 
associated with a progressive buildup of danger signals 
that engage multiple receptors involved in activation of 
inflammatory cells and pro-inflammatory cytokine path-
ways with the prolonged metabolic insult of HF–HS–
HSD. Consistent with this finding, we found a significant 
increase in inflammatory cell recruitment in the liver 
after 27 and 49  weeks of HF–HC–HSD. Macrophages 
are highly plastic and in the inflamed tissues acquire an 
activated M1 phenotype. The M2, alternatively activated 
macrophages express CD163, Arg1, CD206, and produce 
IL-10 and TGFβ with an overall anti-inflammatory func-
tion. In a previous study, an increase in M1 macrophages 
in the liver after a 27  week HFD feeding was seen [56]. 
This group also found an increase in M2 marker expres-
sion in these mice as well as in patients who were mor-
bidly obese. In our study, we observed an increase in M1 
macrophages at the later time points of the HF–HC–
HSD; however in contrast to Wan et  al. [56], we found 
a decrease in expression of M2 macrophage markers 
(CD163, Arg1). The differences that are seen in the M2 
population could be due to the different diets used as 
well as the fact that the mice were fed for 49  weeks in 
our experiment, as opposed to 27 weeks in Wan’s study. 
These changes in the macrophage populations are also 
likely contributing to the development of inflammation 
and fibrosis.
We observed a gradual increase in pro-collagen1, TGF-
β, TIMP-1, TIPM3 and MMP2 markers for fibrosis [43, 
57], whereas αSMA peaked at 27 weeks and decreased at 
49 weeks, this pattern of fibrosis markers was consistent 
with previous findings that αSMA is elevated earlier in 
the development of fibrosis [57, 58]. Progression of fibro-
sis was also evident on Sirius red staining and histology 
analysis. Following fibrosis our HF–HC–HSD induced 
detectable p53 in the liver by weeks 27 and 49 as well as 
tumor development by week 49.
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Conclusions
In summary, the HF–HC–HSD feeding in mice closely 
mimics the progression of human NASH. In this model 
of NASH, we identified a gradual increase in both endog-
enous (HMGB1, uric acid, ATP) and exogenous (LPS) 
danger signals along with up-regulation of their respec-
tive receptor sensors, supporting that multiple cumu-
lative danger signals from metabolic insult results in 
the progression of NAFLD to NASH, fibrosis and liver 
tumors. While our data describes some mechanistic sign-
aling modulations associated with HF–HC–HSD induced 
liver neoplasia, they are by no means an exhaustive list.
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chow or HF-HC-HSD. 8–10 week old C57BL6 mice were fed with chow 
diet or HF‑HC‑HSD for the indicated time points and euthanized as indi‑
cated. All mice received unrestricted access to food and water during the 
entire experiment. Mice bedding and cages were changed every 2 days 
for the entire feeding period.
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Additional file 3: Figure 3S: Liver immunohistology after 49 weeks 
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staining.
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